Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity

Frontiers in Immunology

Volumn 8, Issue , 2017, Pages

  Geeraerts, Xenia ^a,b   Bolli, Evangelia ^a,b   Fendt, Sarah Maria ^a,c   Van Ginderachter, Jo A ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c Katholieke Universiteit   (Belgium)

Author keywords

Cancer; Immunometabolism; Inflammatory diseases; M1 M2 macrophage polarization; Metabolic reprogramming; Metabolic therapy; Microenvironment; Tumor associated macrophages

Indexed keywords

ARGININE; CITRATE SYNTHASE; GAMMA INTERFERON; GLUCOSE TRANSPORTER 1; GLUTAMATE SYNTHASE (NADH); GLUTAMINE; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

AEROBIC GLYCOLYSIS; ANGIOGENESIS; ATHEROSCLEROSIS; CANCER CELL LINE; CITRIC ACID CYCLE; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE OVEREXPRESSION; HEART INFARCTION; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; INFLAMMATORY DISEASE; MACROPHAGE; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASM; METABOLIC REGULATION; METABOLISM; METASTASIS; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

EID: 85016030399     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00289     Document Type: Review

References (105)

1. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 342(6155):1242454. doi:10.1126/science.1242454
2. Ho PC, Liu PS. Metabolic communication in tumors: a new layer of immunoregulation for immune evasion. J Immunother Cancer (2016) 4(1):4. doi:10.1186/s40425-016-0109-1
3. O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol (2016) 16(9):553-65. doi:10.1038/ nri.2016.70
4. O'Neill LA, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med (2016) 213(1):15-23. doi:10.1084/jem.20151570
5. Mills CD, Thomas AC, Lenz LL, Munder M. Macrophage: SHIP of immunity. Front Immunol (2014) 5:620. doi:10.3389/fimmu.2014.00620
6. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol (2011) 27:441-64. doi:10.1146/annurev-cellbio-092910-154237
7. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol (1927) 8(6):519-30. doi:10.1085/jgp.8.6.519
8. Ghesquière B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. Nature (2014) 511(7508):167-76. doi:10.1038/nature13312
9. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 23(3):277-86. doi:10.1016/j. ccr.2013.02.013
10. Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol (2016) 17(1):34-40. doi:10.1038/ni.3324
11. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity (2014) 40(2):274-88. doi:10.1016/j. immuni.2014.01.006
12. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41(1):14-20. doi:10.1016/j.immuni.2014.06.008
13. Mills CD, Harris RA, Ley K. Macrophage polarization: decisions that affect health. J Clin Cell Immunol (2015) 6(5):364. doi:10.4172/2155-9899.1000364
14. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 164(12):6166-73. doi:10.4049/ jimmunol.164.12.6166
15. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 25(12):677-86. doi:10.1016/j.it.2004.09.015
16. Gordon S. Alternative activation of macrophages. Nat Rev Immunol (2003) 3(1):23-35. doi:10.1038/nri978
17. Van Ginderachter JA, Movahedi K, Ghassabeh GH, Meerschaut S, Beschin A, Raes G, et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology (2006) 211(6-8):487-501. doi:10.1016/j.imbio.2006.06.002
18. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab (2012) 15(4):432-7. doi:10.1016/j.cmet.2011.11.013
19. Mills EL, O'Neill LA. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. Eur J Immunol (2016) 46(1):13-21. doi:10.1002/eji.201445427
20. Jha AK, Huang SCC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity (2015) 42(3):419-30. doi:10.1016/j.immuni.2015.02.005
21. Meiser J, Krämer L, Sapcariu SC, Battello N, Ghelfi J, D'Herouel AF, et al. Pro- inflammatory macrophages sustain pyruvate oxidation through pyruvate dehydrogenase for the synthesis of itaconate and to enable cytokine expression. J Bio Chem (2016) 291(8):3932-46. doi:10.1074/jbc.M115.676817
22. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc Natl Acad Sci U S A (2013) 110(19):7820-5. doi:10.1073/pnas.1218599110
23. Cordes T, Wallace M, Michelucci A, Divakaruni AS, Sapcariu SC, Sousa C, et al. Immunoresponsive gene 1 and itaconate inhibit succinate dehydrogenase to modulate intracellular succinate levels. J Biol Chem (2016) 291(27):14274-84. doi:10.1074/jbc.M115.685792
24. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab (2016) 24(1):158-66. doi:10.1016/j. cmet.2016.06.004 doi:10.1038/nature11986
25. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is a danger signal that induces IL-1ß via HIF-1a. Nature (2013) 496(7444):238-42.
26. Lorendeau D, Christen S, Rinaldi G, Fendt SM. Metabolic control of signalling pathways and metabolic auto-regulation. Biol Cell (2015) 107(8):251-72. doi:10.1111/boc.201500015
27. Mills EL, Kelly B, Logan A, Costa AS, Varma M, Bryant CE, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell (2016) 167(2):457-70. doi:10.1016/j. cell.2016.08.064
28. Moon JS, Hisata S, Park MA, DeNicola GM, Ryter SW, Nakahira K, et al. mTORC1-induced HK1-dependent glycolysis regulates NLRP3 inflammasome activation. Cell Rep (2015) 12:102-15. doi:10.1016/j. celrep.2015.05.046
29. Hayashi M, Sakata M, Takeda T, Yamamoto T, Okamoto Y, Sawada K, et al. Induction of glucose transporter 1 expression through hypoxia-inducible factor 1a under hypoxic conditions in trophoblast-derived cells. J Endocrinol (2004) 183(1):145-54. doi:10.1677/joe.1.05599
30. Obach M, Navarro-Sabaté à, Caro J, Kong X, Duran J, Gómez M, et al. 6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. J Biol Chem (2004) 279(51):53562-70. doi:10.1074/jbc.M406096200
31. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1a- dependent mechanism. J Biol Chem (2006) 281(14):9030-7. doi:10.1074/jbc. M511397200
32. Blouin CC, Pagé EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1a. Blood (2004) 103(3):1124-30. doi:10.1182/blood-2003-07-2427
33. Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester MA, et al. Metabolic reprogramming of macrophages glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem (2014) 289(11):7884-96. doi:10.1074/jbc.M113.522037
34. Rodríguez-Prados JC, Través PG, Cuenca J, Rico D, Aragonés J, Martín-Sanz P, et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol (2010) 185(1):605-14. doi:10.4049/jimmunol.0901698
35. Boscá L, González-Ramos S, Prieto P, Fernández-Velasco M, Mojena M, Martín-Sanz P, et al. Metabolic signatures linked to macrophage polarization: from glucose metabolism to oxidative phosphorylation. Biochem Soc Trans (2015) 43(4):740-4. doi:10.1042/BST20150107
36. Tan Z, Xie N, Banerjee S, Cui H, Fu M, Thannickal VJ, et al. The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages. J Biol Chem (2015) 290(1):46-55. doi:10.1074/jbc.M114.603589
37. Qualls JE, Subramanian C, Rafi W, Smith AM, Balouzian L, DeFreitas AA, et al. Sustained generation of nitric oxide and control of mycobacterial infection requires argininosuccinate synthase 1. Cell Host Microbe (2012) 12(3):313-23. doi:10.1016/j.chom.2012.07.012
38. Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 95(13):7631-6. doi:10.1073/pnas.95.13.7631
39. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res (2015) 25(7):771-84. doi:10.1038/cr.2015.68
40. Van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, et al. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep (2016) 17(3):684-96. doi:10.1016/j. celrep.2016.09.008
41. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y. The reactive oxygen species in macrophage polarization: reflecting its dual role in progression and treatment of human diseases. Oxid Med Cell Longev (2016) 2016:16. doi:10.1155/2016/2795090
42. West AP, Brodsky IE, Rahner C, Woo DK, Erdjument-Bromage H, Tempst P, et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature (2011) 472(7344):476-80. doi:10.1038/ nature09973
43. Infantino V, Convertini P, Cucci L, Panaro MA, Di Noia MA, Calvello R, et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem J (2011) 438(3):433-6. doi:10.1042/BJ20111275
44. Infantino V, Iacobazzi V, Palmieri F, Menga A. ATP-citrate lyase is essential for macrophage inflammatory response. Biochem Biophys Res Commun (2013) 440(1):105-11. doi:10.1016/j.bbrc.2013.09.037
45. Infantino V, Iacobazzi V, Menga A, Avantaggiati ML, Palmieri F. A key role of the mitochondrial citrate carrier (SLC25A1) in TNFa-and IFN-triggered inflammation. Biochim Biophys Acta (2014) 1839(11):1217-25. doi:10.1016/j. bbagrm.2014.07.013
46. Baardman J, Licht I, de Winther MP, Van den Bossche J. Metabolic-epigenetic crosstalk in macrophage activation. Epigenomics (2015) 7(7):1155-64. doi:10.2217/epi.15.71
47. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science (2009) 324(5930):1076-80. doi:10.1126/science.1164097
48. Feingold KR, Shigenaga JK, Kazemi MR, McDonald CM, Patzek SM, Cross AS, et al. Mechanisms of triglyceride accumulation in activated macrophages. J Leukocyte Biol (2012) 92(4):829-39. doi:10.1189/jlb.1111537
49. Ecker J, Liebisch G, Englmaier M, Grandl M, Robenek H, Schmitz G. Induction of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes. Proc Natl Acad Sci U S A (2010) 107(17):7817-22. doi:10.1073/pnas.0912059107
50. Galván-Peña S, O'Neill LA. Metabolic reprograming in macrophage polarization. Front Immunol (2014) 5:420. doi:10.3389/fimmu.2014.00420
51. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, et al. Oxidative metabolism and PGC-1ß attenuate macrophage-mediated inflammation. Cell Metab (2006) 4(1):13-24. doi:10.1016/j.cmet.2006.05.011
52. Huang SC, Everts B, Ivanova Y, O'Sullivan D, Nascimento M, Smith AM, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol (2014) 15(9):846-55. doi:10.1038/ni.2956
53. Malandrino MI, Fucho R, Weber M, Calderon-Dominguez M, Mir JF, Valcarcel L, et al. Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation. Am J Physiol Endocrinol Metab (2015) 308(9):756-69. doi:10.1152/ ajpendo.00362.2014
54. Nomura M, Liu J, Rovira II, Gonzalez-Hurtado E, Lee J, Wolfgang MJ, et al. Fatty acid oxidation in macrophage polarization. Nat Immunol (2016) 17(3):216-7. doi:10.1038/ni.3366
55. Chawla A. Control of macrophage activation and function by PPARs. Circ Res (2010) 106(10):1559-69. doi:10.1161/CIRCRESAHA.110.216523
56. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature (2007) 447(7148):1116-20. doi:10.1038/nature05894
57. Coste A, Dubourdeau M, Linas MD, Cassaing S, Lepert JC, Balard P, et al. PPAR promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. Immunity (2003) 19(3):329-39. doi:10.1016/S1074-7613(03)00229-2
58. Rath M, Müller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol (2014) 5:532. doi:10.3389/fimmu.2014.00532
59. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH 1 and TH 2 cytokines. Eur J Immunol (1995) 25(4):1101-4. doi:10.1002/eji.1830250436
60. Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, Murray PJ. Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol (2004) 172(12):7565-73. doi:10.4049/jimmunol.172.12.7565
61. Gallardo-Soler A, Gómez-Nieto C, Campo ML, Marathe C, Tontonoz P, Castrillo A, et al. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-/d-mediated effect that links lipid metabolism and immunity. Mol Endocrinol (2008) 22(6):1394-402. doi:10.1210/me.2007-0525
62. Hardbower DM, Asim M, Luis PB, Singh K, Barry DP, Yang C, et al. Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications. Proc Natl Acad Sci U S A (2017) 114(5):E751-60. doi:10.1073/pnas.1614958114
63. Haschemi A, Kosma P, Gille L, Evans CR, Burant CF, Starkl P, et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab (2012) 15(6):813-26. doi:10.1016/j. cmet.2012.04.023
64. Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta (2016) 1865(1):23-34. doi:10.1016/j.bbcan.2015.06.009
65. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 10(4):267-77. doi:10.1038/nrc2817
66. Elia I, Schmieder R, Christen S, Fendt SM. Organ-specific cancer metabolism and its potential for therapy. Handb Exp Pharmacol (2016) 233:321-53. doi:10.1007/164_2015_10
67. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One (2012) 7(12):e50946. doi:10.1371/journal. pone.0050946
68. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 141(1):39-51. doi:10.1016/j.cell.2010.03.014
69. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res (2010) 70(14):5728-39. doi:10.1158/0008-5472.CAN-09-4672
70. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res (2014) 74(1):24-30. doi:10.1158/0008-5472.CAN-13-1196
71. Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, et al. M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res (2016) 76(1):35-42. doi:10.1158/0008-5472.CAN-15-0869
72. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol (2008) 180(4):2011-7. doi:10.4049/jimmunol.180.4.2011
73. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med (2015) 212(4):435-45. doi:10.1084/jem.20150295
74. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res (2007) 67(19):9417-24. doi:10.1158/0008-5472.CAN-07-1286
75. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res (2013) 19(13):3404-15. doi:10.1158/1078-0432.CCR-13-0525
76. Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol (2013) 71(4):1041-50. doi:10.1007/s00280-013-2099-8
77. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature (2014) 515(7525):130-3. doi:10.1038/nature13862
78. Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 16(7):447-62. doi:10.1038/nrc.2016.54
79. Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell (2013) 24(6):695-709. doi:10.1016/j.ccr.2013.11.007
80. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 19(10):1264-72. doi:10.1038/nm.3337
81. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature (2014) 513(7519):559-63. doi:10.1038/ nature13490
82. Penny HL, Sieow JL, Adriani G, Yeap WH, See Chi Ee P, San Luis B, et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. Oncoimmunology (2016) 5(8):e1191731. doi:10.1080/2162402X. 2016.1191731
83. Wenes M, Shang M, Di Matteo M, Goveia J, Martín-Pérez R, Serneels J, et al. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab (2016) 24(5):701-15. doi:10.1016/j.cmet.2016.09.008
84. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab (2013) 18(2):153-61. doi:10.1016/j. cmet.2013.05.017
85. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2010) 120(1):142-56. doi:10.1172/JCI38942
86. Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta (2011) 1807(6):726-34. doi:10.1016/j. bbabio.2010.10.022
87. Schoors S, Bruning U, Missiaen R, Queiroz KC, Borgers G, Elia I, et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature (2015) 520(7546):192-7. doi:10.1038/nature14362
88. Chang C-H, Pearce EL. Emerging concepts in immunotherapy-T cell metabolism as a therapeutic target. Nat Immunol (2016) 17(4):364-8. doi:10.1038/ni.3415
89. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun (2015) 6:6692. doi:10.1038/ ncomms7692
90. Verdegem D, Moens S, Stapor P, Carmeliet P. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab (2014) 2:19. doi:10.1186/2049-3002-2-19
91. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol (2013) 13(10):709-21. doi:10.1038/nri3520
92. Peled M, Fisher EA. Dynamic aspects of macrophage polarization during atherosclerosis progression and regression. Front Immunol (2014) 5:579. doi:10.3389/fimmu.2014.00579
93. Stöger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis (2012) 225(2):461-8. doi:10.1016/j. atherosclerosis.2012.09.013
94. Hanna RN, Shaked I, Hubbeling HG, Punt JA, Wu R, Herrley E, et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res (2012) 110(3):416-27. doi:10.1161/ CIRCRESAHA.111.253377
95. Sharma N, Lu Y, Zhou G, Liao X, Kapil P, Anand P, et al. Myeloid Krüppel- like factor 4 deficiency augments atherogenesis in ApoE-/- mice-brief report. Arterioscler Thromb Vasc Biol (2012) 32(12):2836-8. doi:10.1161/ ATVBAHA.112.300471
96. Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med (2012) 4(10):1072-86. doi:10.1002/emmm.201201374
97. Feig JE, Parathath S, Rong JX, Mick SL, Vengrenyuk Y, Grauer L, et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation (2011) 123(9):989-98. doi:10.1161/CIRCULATIONAHA.110.984146
98. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A (2011) 108(17):7166-71. doi:10.1073/pnas.1016086108
99. Ouimet M, Ediriweera HN, Gundra UM, Sheedy FJ, Ramkhelawon B, Hutchison SB, et al. microRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Invest (2015) 125(12):4334-48. doi:10.1172/JCI81676
100. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 112(12):1796-808. doi:10.1172/JCI19246
101. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest (2007) 117(1):175-84. doi:10.1172/JCI29881
102. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest (2010) 120(10):3466-79. doi:10.1172/JCI42845
103. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-a function. Nature (1997) 389(6651):610-4. doi:10.1038/39335
104. Xu X, Grijalva A, Skowronski A, van Eijk M, Serlie MJ, Ferrante AW Jr. Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab (2013) 18(6):816-30. doi:10.1016/j.cmet.2013.11.001
105. Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, Peris E, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab (2014) 20(4):614-25. doi:10.1016/j. cmet.2014.08.010